Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2000 Jun;68(6):707–712. doi: 10.1136/jnnp.68.6.707

Botulinum toxin (Dysport®) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study

N Hyman 1, M Barnes 1, B Bhakta 1, A Cozens 1, M Bakheit 1, B Kreczy-Kleedorfer 1, W Poewe 1, J Wissel 1, P Bain 1, S Glickman 1, A Sayer 1, A Richardson 1, C Dott 1
PMCID: PMC1736956  PMID: 10811692

Abstract

OBJECTIVE—To define a safe and effective dose of Dysport for treating hip adductor spasticity.
METHODS—Patients with definite or probable multiple sclerosis, and disabling spasticity affecting the hip adductor muscles of both legs, were randomised to one of four treatment groups. Dysport (500, 1000, or 1500 Units), or placebo was administered by intramuscular injection to these muscles. Patients were assessed at entry, and 2, 4 (primary analysis time-point), 8, and 12 weeks post-treatment.
RESULTS—A total of 74 patients were recruited. Treatment groups were generally well matched at entry. The primary efficacy variables—passive hip abduction and distance between the knees—improved for all groups. The improvement in distance between the knees for the 1500 Unit group was significantly greater than placebo (p=0.02). Spasm frequency was reduced in all groups, but muscle tone was reduced in the Dysport groups only. Pain was reduced in all groups, but improvements in hygiene scores were evident only in the 1000Unit and 1500 Unit groups. Duration of benefit was significantly longer than placebo for all Dysport groups (p<0.05). Adverse events were reported by 32/58 (55%) Dysport patients, and by 10/16 (63%) placebo patients. Compared with the two lower dose groups, twice as many adverse events were reported by the 1500 Unit group (2.7/patient). The incidence of muscle weakness was higher for the 1500 Unit group (36%) than for placebo (6%). The response to treatment was considered positive by two thirds of the patients in the 500 Unit group, and by about half the patients in the other groups.
CONCLUSION—Dysport reduced the degree of hip adductor spasticity associated with multiple sclerosis, and this benefit was evident despite the concomitant use of oral antispasticity medication and analgesics. Although evidence for a dose response effect was not statistically significant, there was a clear trend towards greater efficacy and duration of effect with higher doses of Dysport. Dysport treatment was well tolerated, with no major side effects seen at doses up to 1500 Units. The optimal dose for hip adductor spasticity seems to be 500-1000 Units, divided between both legs.



Full Text

The Full Text of this article is available as a PDF (146.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blackie J. D., Lees A. J. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry. 1990 Aug;53(8):640–643. doi: 10.1136/jnnp.53.8.640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brans J. W., Lindeboom R., Snoek J. W., Zwarts M. J., van Weerden T. W., Brunt E. R., van Hilten J. J., van der Kamp W., Prins M. H., Speelman J. D. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology. 1996 Apr;46(4):1066–1072. doi: 10.1212/wnl.46.4.1066. [DOI] [PubMed] [Google Scholar]
  3. Das T. K., Park D. M. Effect of treatment with botulinum toxin on spasticity. Postgrad Med J. 1989 Apr;65(762):208–210. doi: 10.1136/pgmj.65.762.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Elston J. S. The management of blepharospasm and hemifacial spasm. J Neurol. 1992 Jan;239(1):5–8. doi: 10.1007/BF00839203. [DOI] [PubMed] [Google Scholar]
  5. Mémin B., Pollak P., Hommel M., Perret J. Traitement de la spasticité par la toxine botulique. Rev Neurol (Paris) 1992;148(3):212–214. [PubMed] [Google Scholar]
  6. Odergren T., Hjaltason H., Kaakkola S., Solders G., Hanko J., Fehling C., Marttila R. J., Lundh H., Gedin S., Westergren I. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):6–12. doi: 10.1136/jnnp.64.1.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Poewe W., Deuschl G., Nebe A., Feifel E., Wissel J., Benecke R., Kessler K. R., Ceballos-Baumann A. O., Ohly A., Oertel W. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):13–17. doi: 10.1136/jnnp.64.1.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Snow B. J., Tsui J. K., Bhatt M. H., Varelas M., Hashimoto S. A., Calne D. B. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990 Oct;28(4):512–515. doi: 10.1002/ana.410280407. [DOI] [PubMed] [Google Scholar]
  9. Yoshimura D. M., Aminoff M. J., Olney R. K. Botulinum toxin therapy for limb dystonias. Neurology. 1992 Mar;42(3 Pt 1):627–630. doi: 10.1212/wnl.42.3.627. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES